Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Etoposide in Pediatric Ependymoma
NCT01032070Phase 2Terminated
- Sponsor
- OSI Pharmaceuticals
- Start
- Sep 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of erlotinib in ependymoma, sponsored by OSI Pharmaceuticals. Started Sep 2010; status: terminated.
02
Drugs
erlotinib
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT01032070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01032070.